1246815-16-6
1246815-16-6
Chemical Structure
Efaproxiral-d6
Synonym(s): RSR13-d6
- CAS No.: 1246815-16-6
- Formula:C20H17D6NO4
- Molecular Weight:347.44
IUPAC Name: 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-(methyl-d3)propanoic-3,3,3-d3 acid
InChIKey: BNFRJXLZYUTIII-LIJFRPJRSA-N
SMILES: O(C(C(O)=O)(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1
Biological Activity: Efaproxiral (RSR13)-d6 is the deuterium labeled Efaproxiral (HY-13619). Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy [1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Efaproxiral-d6 | Efaproxiral (RSR13)-d6 is the deuterium labeled Efaproxiral (HY-13619). Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Efaproxiral (Standard) | ≥98% | Efaproxiral (RSR13) (Standard) is the analytical standard of Efaproxiral (HY-13619). This product is intended for research and analytical applications. Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Efaproxiral | 99.94% | Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier. Efaproxiral decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784. [Content Brief]
- [2]. Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31(38):9141-9. [Content Brief]
- [3]. Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168(2):218-25. [Content Brief]
- [4]. Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9. [Content Brief]
